The QWINT-1 study compared efsitora to daily injections of Sanofi’s SNY Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared ...

Such forward looking statements may include statements about the approval for the first interchangeable biosimilar Semglee (insulin glargine-yfgn injection) for the treatment of diabetes ...

Insulin glargine is produced by recombinant DNA technology ... 4 to 6.7. It results in an insulin molecule less soluble at the injection site, that precipitates in the subcutaneous tissue forming ...

Fröhlich-Reiterer and colleagues, therefore, compared the effects of insulin glargine in several regimens of three injections daily in prepubertal children. This randomized, crossover study ...

Insulin glargine, at a therapeutic concentration ... These molecular changes cause the drug to precipitate upon subcutaneous injection, increasing stability and duration of action.